Evolving Science Development of Cancer Metabolism-Based Therapies

APR 7 2020

This time we invited Mr. Ben R. Taylor, President & CFO at TYME, as well as other senior executives at TYME to share their views on how the company's cancer metabolism-based therapies will help fight against cancer.

Moderator:

• Mr. Marc Estigarribia, Senior Partner & Manager Director at MSQ

Invited guests:

• Mr. Ben R. Taylor, Chairman and CEO at TYME

• Dr. Shawn Shi, Venture Partner at MSQ

About TYME:

TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

For more info, please visit here.